Johnson & Johnson Gains Momentum from Dual Growth Engines

Oncology Drug Delivers Explosive Growth

Johnson & Johnson is demonstrating robust performance across its two primary business segments. The company’s oncology franchise is being powered by its CAR-T cell therapy, Carvykti, which is experiencing remarkable revenue expansion. Simultaneously, its medical devices division received a significant boost from compelling new long-term data for the Impella CP heart pump. Alongside these successes, the healthcare giant is also making strategic decisions to refine its development pipeline.